Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3

被引:0
|
作者
Stéphane Califice
Vincent Castronovo
Marc Bracke
Frédéric van den Brûle
机构
[1] Metastasis Research Laboratory,Department of Radiotherapy and Nuclear Medicine
[2] Experimental Cancer Research Center,Department of Gynecology
[3] University of Liège,undefined
[4] Laboratory of Experimental Cancerology,undefined
[5] Ghent University Hospital,undefined
[6] University of Liège,undefined
来源
Oncogene | 2004年 / 23卷
关键词
galectin-3; prostate cancer; nucleus; cytoplasm;
D O I
暂无
中图分类号
学科分类号
摘要
Galectin-3, a multifunctional lectin, is involved during cancer progression. Previous observations showed that both cytosolic expression and nuclear exclusion of galectin-3 in human prostate cancer cells were associated to progression of the disease. In this study, we examined the biological roles of galectin-3 when expressed either in the nucleus or in the cytosol. LNCaP, a galectin-3-negative human prostate cancer cell line, was used to generate transfectants expressing galectin-3 either in the nucleus or in the cytosol. No changes in cell morphology, proliferation, attachment to laminin-1 or androgen dependency were observed. Cytoplasmic galectin-3 induced significantly increased Matrigel invasion, anchorage-independent growth and in vivo tumor growth and angiogenesis, and decreased inducible apoptosis. Surprisingly, nuclear galectin-3 affected these parameters in an opposite fashion with an overall antitumoral activity. Thus, our study demonstrates that galectin-3 exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression.
引用
收藏
页码:7527 / 7536
页数:9
相关论文
共 50 条
  • [1] Dual activities of galectin-3 in human prostate cancer:: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3
    Califice, S
    Castronovo, V
    Bracke, M
    van den Brûle, F
    ONCOGENE, 2004, 23 (45) : 7527 - 7536
  • [2] Galectin-3 in tumor metastasis
    Akahani, S
    Inohara, H
    NangiaMakker, P
    Raz, A
    TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, 1997, 9 (45) : 69 - 75
  • [3] Galectin-3 in cancer
    Song, Lin
    Tang, Jian-wu
    Owusu, Lawrence
    Sun, Ming-Zhong
    Wu, Jun
    Zhang, Jun
    CLINICA CHIMICA ACTA, 2014, 431 : 185 - 191
  • [4] Galectin-3 and cancer
    Califice, S
    Castronovo, V
    Van Den Brûle, F
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (04) : 983 - 992
  • [5] Galectin-3 and galectin-3 binding protein in rheumatoid arthritis
    Ohshima, S
    Kuchen, S
    Seemayer, C
    Liu, FT
    Neidhart, M
    Gay, RE
    Gay, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S43 - S43
  • [6] Galectin-3 and galectin-3 binding protein in rheumatoid arthritis
    S Ohshima
    S Kuchen
    C Seemayer
    FT Liu
    M Neidhart
    RE Gay
    S Gay
    Arthritis Res Ther, 5
  • [7] Galectin-3 and cancer stemness
    Nangia-Makker, Pratima
    Hogan, Victor
    Raz, Avraham
    GLYCOBIOLOGY, 2018, 28 (04) : 172 - 181
  • [8] The roles of Galectin-3 in autoimmunity and tumor progression
    Gordana Radosavljevic
    Vladislav Volarevic
    Ivan Jovanovic
    Marija Milovanovic
    Nada Pejnovic
    Nebojsa Arsenijevic
    Daniel K. Hsu
    Miodrag L. Lukic
    Immunologic Research, 2012, 52 : 100 - 110
  • [9] Thyroid Cancer and Galectin-3
    Hasbek, Z.
    Duman, G.
    Candar, T.
    Erturk, S. A.
    Cakmakcilar, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S780 - S781
  • [10] The roles of Galectin-3 in autoimmunity and tumor progression
    Radosavljevic, Gordana
    Volarevic, Vladislav
    Jovanovic, Ivan
    Milovanovic, Marija
    Pejnovic, Nada
    Arsenijevic, Nebojsa
    Hsu, Daniel K.
    Lukic, Miodrag L.
    IMMUNOLOGIC RESEARCH, 2012, 52 (1-2) : 100 - 110